Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Inventiva ( (IVA) ) just unveiled an update.
On February 17, 2026, Inventiva reported preliminary unaudited results for the fiscal year ended December 31, 2025, highlighting cash and cash equivalents of €99.3 million and €131.6 million in short-term deposits, alongside 2025 revenues of €4.5 million, down from €9.2 million in 2024. The company completed a U.S. public equity offering in November 2025 that raised gross proceeds of about $172.5 million (€149 million), and together with a second tranche of structured financing in May 2025, this lifted net cash from financing activities to €241.1 million for the year.
Net cash used in operating activities rose 22% year-on-year to €104.6 million in 2025, driven by the impact of a pipeline prioritization plan, lower license revenues from partner CTTQ, and higher general and administrative expenses, even as R&D spending on lanifibranor fell 4% to €86.9 million. Management now projects that the current cash, cash equivalents, and short-term deposits will fund operations until the middle of the first quarter of 2027, with potential additional runway to the middle of the third quarter of 2027 if certain warrants from the 2024 structured financing are fully exercised, underlining both strengthened liquidity after 2025 capital raises and ongoing funding needs typical of a late-stage MASH-focused biotech.
The most recent analyst rating on (IVA) stock is a Sell with a $6.00 price target. To see the full list of analyst forecasts on Inventiva stock, see the IVA Stock Forecast page.
Spark’s Take on IVA Stock
According to Spark, TipRanks’ AI Analyst, IVA is a Neutral.
The score is held down primarily by weak financial performance (ongoing losses, negative equity, and negative operating/free cash flow). Technicals provide a meaningful offset due to a clear uptrend and positive momentum, while valuation remains unfavorable given the loss-making profile and no dividend support.
To see Spark’s full report on IVA stock, click here.
More about Inventiva
Inventiva is a clinical-stage biopharmaceutical company specializing in oral small molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH), a progressive chronic liver disease. Its lead candidate, lanifibranor, a novel pan-PPAR agonist, is currently being evaluated in the pivotal Phase 3 NATiV3 trial in adult MASH patients, and the company is dual-listed on Euronext Paris and the Nasdaq Global Market.
Average Trading Volume: 396,747
Technical Sentiment Signal: Buy
Current Market Cap: $1.29B
For a thorough assessment of IVA stock, go to TipRanks’ Stock Analysis page.